Summit Therapeutics
SMMT
21 hedge funds and large institutions have $44.5M invested in Summit Therapeutics in 2017 Q4 according to their latest regulatory filings, with 2 funds opening new positions, 5 increasing their positions, 3 reducing their positions, and 2 closing their positions.
67% more repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 3
0% more funds holding
Funds holding: 21 → 21 (0)
0% more first-time investments, than exits
New positions opened: 2 | Existing positions closed: 2
0.08% less ownership
Funds ownership: 5.77% → 5.69% (-0.08%)
12% less capital invested
Capital invested by funds: $50.9M → $44.5M (-$6.35M)
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Acadian Asset Management
Boston,
Massachusetts
|
+$1.06M |
| 2 |
Morgan Stanley
New York
|
+$770K |
| 3 |
Millennium Management
New York
|
+$254K |
| 4 |
First Eagle Investment Management
New York
|
+$223K |
| 5 |
Renaissance Technologies
New York
|
+$174K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$1.83M |
| 2 |
KCM
Knoll Capital Management
Miami,
Florida
|
-$1.15M |
| 3 |
Point72 Asset Management
Stamford,
Connecticut
|
-$233K |
| 4 |
UBS Group
Zurich,
Switzerland
|
-$32.4K |
| 5 |
Axa
Paris,
France
|
-$2.69K |
SMMT Hedge Fund Activity: Q4 2017 in Review
21 of the 4,419 institutional investors tracked by Wall St. Rank reported a position in Summit Therapeutics (SMMT) for Q4 2017, worth a combined $44.5M — down 12% from $50.9M a quarter earlier.
Fund positioning in SMMT was balanced in Q4 2017: 2 funds opened new positions, 2 closed out, 5 added to existing stakes and 3 trimmed.
The largest buyer was Acadian Asset Management, adding an estimated $1.06M. The largest seller was Susquehanna International Group, exiting entirely with an estimated $1.83M sold.
- 21 institutional investors held Summit Therapeutics (SMMT) as of Q4 2017, unchanged from Q3 2017.
- Funds reported $44.5M of Summit Therapeutics stock for Q4 2017, down 12% quarter-over-quarter.
- 2 funds opened new Summit Therapeutics positions in Q4 2017 and 2 closed out, a net change of 0 holders.
- The largest Summit Therapeutics buyer in Q4 2017 was Acadian Asset Management, an estimated $1.06M added.
- The largest Summit Therapeutics seller in Q4 2017 was Susquehanna International Group, an estimated $1.83M sold.
Based on aggregated 13F filings for Q4 2017.